Oral antiviral molnupiravir reduces hospitalization and death risk for high-risk Covid-19 patients
In short: A phase 3, double-blind, randomized trial of 1,433 unvaccinated adults with mild-to-moderate Covid-19 found that the oral antiviral molnupiravir significantly lowered the risk of hospitalization or death. Participants who received the drug within five days of symptom onset showed a lower incidence of severe outcomes compared to those receiving a placebo.
The study aimed to evaluate how effectively molnupiravir could prevent disease progression in patients with at least one risk factor for severe illness. The results showed that the treatment reduced the risk of hospitalization or death by approximately 3 percentage points among all randomized participants.
While the drug was effective overall, some subgroups—including those with previous infections or diabetes—showed mixed results where the benefit was less clear. A primary limitation of this study is that it only included unvaccinated individuals.
Why it matters: Early antiviral treatment can help prevent severe outcomes for high-risk patients who develop mild-to-moderate Covid-19.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Jayk et al. (2022). Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-oral-antiviral-molnupiravir-reduces-hospitalization-and-deat.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
